 Anti-PD-1 Antibody |
|||
| A1384-30T | Biovision | EUR 146 | |
 Anti-PD-1 antibody |
|||
| STJ190081 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Unconjugated Mouse monoclonal to PD-1 (AS1A13) |
|||
 XStamp Pro anti-PD-1 EV Targeting Kit |
|||
| XSTP915A-1 | SBI | 10 rxn | EUR 805 |
 Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 349 |
 Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
 PD 173074 |
|||
| 1675-1 | Biovision | EUR 137 | |
 PD 166326 |
|||
| C3677-1 | ApexBio | 1 mg | EUR 161 |
|
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. |
|||
 PD 198306 |
|||
| B7124-1 | ApexBio | 1 mg | EUR 126 |
|
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). |
|||
 Anti-PD-1 Biotinylated Antibody |
|||
| A1996-100 | Biovision | 100 µg | EUR 343 |
Anti-PD-1 Biotinylated Antibody |
|||
| A1996-30 | Biovision | 30 µg | EUR 156 |
 Anti-PD-1/CD279 antibody |
|||
| PAab06234 | Lifescience Market | 100 ug | EUR 412 |
 antibody) Anti-PD-1 (PDCD1) antibody |
|||
| STJ180216 | St John's Laboratory | 0.1 ml | EUR 212 |
 anti- PD-1/CD279 antibody |
|||
| FNab06234 | FN Test | 100µg | EUR 585 |
|
Description: Antibody raised against PD-1/CD279 |
|||
anti- PD-1/CD279 antibody |
|||
| FNab06235 | FN Test | 100µg | EUR 585 |
|
Description: Antibody raised against PD-1/CD279 |
|||
 mAbConjugated Antibody) Mouse Anti-Human CD279 (PD-1) mAbConjugated Antibody |
|||
| CCM019 | SAB | 100ul | EUR 397 |
 Biotinylated Antibody) Anti-PD-1 (Pembrolizumab) Biotinylated Antibody |
|||
| A2073-50 | Biovision | 50 µg | EUR 379 |
 Biotinylated Antibody) Anti-PD-1 (Nivolumab) Biotinylated Antibody |
|||
| A2117-100 | Biovision | 100 µg | EUR 343 |
Anti-PD-1 (Nivolumab) Biotinylated Antibody |
|||
| A2117-30T | Biovision | 30 µg | EUR 156 |
 humanized Antibody) Anti-PD-1 (Spartalizumab) humanized Antibody |
|||
| A2131-100 | Biovision | 100 µg | EUR 530 |
 humanized Antibody) Anti-PD-1 (Camrelizumab) humanized Antibody |
|||
| A2132-100 | Biovision | 100 µg | EUR 530 |
, Humanized Antibody) Anti-PD-1 (Toripalimab), Humanized Antibody |
|||
| A2161-100 | Biovision | 100 µg | EUR 510 |
, humanized Antibody) Anti-PD-1 (Pembrolizumab), humanized Antibody |
|||
| A1306-100 | Biovision | EUR 501 | |
 PD-1 Antibody |
|||
| 24505-100ul | SAB | 100ul | EUR 390 |
PD-1 Antibody |
|||
| 24506-100ul | SAB | 100ul | EUR 390 |
PD-1 Antibody |
|||
| P1001-01m | SAB | 0.1m | EUR 165 |
PD-1 Antibody |
|||
| P1001-1ml | SAB | 1ml | EUR 376 |
 mAb) Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM019-100ug | SAB | 100ug | EUR 281 |
Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM019-25ug | SAB | 25ug | EUR 165 |
Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM020-100ug | SAB | 100ug | EUR 281 |
Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM020-25ug | SAB | 25ug | EUR 165 |
Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM021-100ug | SAB | 100ug | EUR 281 |
Mouse Anti-Human CD279 (PD-1) mAb |
|||
| CM021-25ug | SAB | 25ug | EUR 165 |
 Anti-PD-L1 Antibody |
|||
| A1454-100 | Biovision | EUR 338 | |
Anti-PD-L1 Antibody |
|||
| A1454-30T | Biovision | EUR 146 | |
 Anti-PD-ECGF antibody |
|||
| PAab06264 | Lifescience Market | 100 ug | EUR 412 |
 Anti-PD-ECGF Antibody |
|||
| A06329 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal Antibody for PD-ECGF Antibody (TYMP) detection.tested for IHC, WB in Human. |
|||
 Anti-PD-L1 antibody |
|||
| STJ130022 | St John's Laboratory | 50 µl | EUR 321 |
|
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
| STJ130023 | St John's Laboratory | 50 µl | EUR 321 |
|
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
| STJ130024 | St John's Laboratory | 50 µl | EUR 321 |
|
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
| STJ180217 | St John's Laboratory | 0.1 ml | EUR 280 |
Anti-PD-L1 antibody |
|||
| STJ180383 | St John's Laboratory | 0.1 ml | EUR 246 |
Anti-PD-L1 antibody |
|||
| STJ190082 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7) |
|||
Anti-PD-ECGF antibody |
|||
| STJ96779 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to PD-ECGF. |
|||
 Anti-PD-L2 antibody |
|||
| STJ98748 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to PD-L2. |
|||
 anti- PD-ECGF antibody |
|||
| FNab06264 | FN Test | 100µg | EUR 585 |
|
Description: Antibody raised against PD-ECGF |
|||
 PD-1/PD-L1 Inhibitor 1 |
|||
| B1213-25 | Biovision | EUR 566 | |
 PD-1/PD-L1 inhibitor 1 |
|||
| B6172-25 | ApexBio | 25 mg | EUR 453 |
|
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
|||
PD-1/PD-L1 inhibitor 1 |
|||
| B6172-5 | ApexBio | 5 mg | EUR 168 |
|
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
|||
 (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320) Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 |
|||
| M00109-1 | BosterBio | 100uL | EUR 427 |
|
Description: Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 tested in WB, IHC, reactive to Human |
|||
 Mouse Anti-Human PD-1 monoclonal antibody, clone JID112 |
|||
| CABT-L2940-100uL500uL | Creative Diagnostics | 100 uL, 500 uL | EUR 502 |